Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 18 Mar 2024
In a full day of meetings, the FDA advisory panel will assess the evidence for cilta-cel and ide-cel.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Why breast cancer survivors don't take their medicine, and what can be done about it.
2.
A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.
3.
Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam Method
4.
The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.
5.
Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?
1.
Oncology Treatment: Innovations, Education, and Clinical Practice Insights
2.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
3.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
4.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
5.
Deep Learning Fluorescence Imaging for Oral Cancer Surgery: In Silico Depth Quantification
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
2.
Clinical Excellence in Hematology
3.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
Diagnosis and Management in Hematology
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge